 |
|
MK-927: A Topical Carbonic Anhydrase InhibitorDose Response and Duration of Action
Eve J. Higginbotham, MD;
Michael A. Kass, MD;
Erik A. Lippa, MD, PhD;
Randal L. Batenhorst, PharmD;
Deborah L. Panebianco, MS;
Jacob T. Wilensky, MD
Arch Ophthalmol. 1990;108(1):65-68.
Abstract
| |
• The dose response to a single topical administration of the carbonic anhydrase inhibitor MK-927 was investigated in 24 patients with primary open angle glaucoma or ocular hypertension. Three concentrations of MK-927 (2%, 1%, and 0.5%) and placebo were administered in a two-center, double-masked, randomized, placebo-controlled, four-period crossover study. MK-927 at the 0.5% concentration appeared to be minimally effective in reducing intraocular pressure. A single topical dose of 1% MK-927 resulted in a significantly greater percent reduction in intraocular pressure for up to 6 hours when compared with treatment with placebo. Similarly, a single dose of 2% MK-927 significantly lowered intraocular pressure for 8 hours compared with treatment with placebo. The pressure reduction from baseline measured 23.7% and 11.3% at 8 hours after instillation of a single drop of 2% MK-927. The medication was well tolerated and appeared to lower intraocular pressure in a dose-dependent fashion.
Author Affiliations
From the Departments of Ophthalmology, Eye and Ear Infirmary, University of Illinois at Chicago (Drs Higginbotham, Batenhorst, and Wilensky), and Washington University School of Medicine, St Louis, Mo (Dr Kass); and Merck Sharp & Dohme Research Laboratories, Clinical Research and Biostatistics, West Point, Pa (Dr Lippa and Ms Panebianco).
Footnotes
Accepted for publication September 20, 1989.
Reprint requests to Eye and Ear Infirmary, University of Illinois at Chicago, 1855 W Taylor St, Room 278, Chicago, IL 60612 (Dr Higginbotham).
Dr Lippa and Ms Panebianco are employed at Merck Sharp & Dohme Research Laboratories. Drs Higginbotham, Kass, Batenhorst, and Wilensky have no commercial or proprietary interest in the drug mentioned herein or in Merck Sharp & Dohme.
We wish to acknowledge the contributions of Coleen Clineschmidt, Medical Program Coordinator, Merck Sharp & Dohme Research Laboratories, for assistance in coordinating the various aspects of this study, and Cathy Reiter for technical assistance at the Department of Ophthalmology, University of Illinois at Chicago.
Preliminary data relating to the manuscript were presented at the American Academy of Ophthalmology meeting, Las Vegas, Nev, October 10, 1988.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Topical carbonic anhydrase inhibition increases ocular pulse amplitude in high tension primary open angle glaucoma
Schmidt et al.
Br J Ophthalmol 1998;82:758-762.
ABSTRACT
| FULL TEXT
Four-Week Safety and Efficacy Study of Dorzolamide, a Novel, Active Topical Carbonic Anhydrase Inhibitor
Wilkerson et al.
Arch Ophthalmol 1993;111:1343-1350.
ABSTRACT
Randomized Clinical Trials on Medical Treatment of Glaucoma: Are They Appropriate to Guide Clinical Practice?
Rossetti et al.
Arch Ophthalmol 1993;111:96-103.
ABSTRACT
Dose Response and Duration of Action of Dorzolamide, a Topical Carbonic Anhydrase Inhibitor
Lippa et al.
Arch Ophthalmol 1992;110:495-499.
ABSTRACT
MK-507 (L-671,152), a Topically Active Carbonic Anhydrase Inhibitor, Reduces Aqueous Humor Production in Monkeys
Wang et al.
Arch Ophthalmol 1991;109:1297-1299.
ABSTRACT
Topically Active Carbonic Anhydrase Inhibitors for Glaucoma
Podos and Serle
Arch Ophthalmol 1991;109:38-40.
ABSTRACT
Multiple-Dose, Dose-Response Relationship for the Topical Carbonic Anhydrase Inhibitor MK-927
Lippa et al.
Arch Ophthalmol 1991;109:46-49.
ABSTRACT
Multiple-Dose Efficacy Comparison of the Two Topical Carbonic Anhydrase Inhibitors Sezolamide and MK-927
Bron et al.
Arch Ophthalmol 1991;109:50-53.
ABSTRACT
|
